Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Amortization of Deferred Charges: 2013-2023

Historic Amortization of Deferred Charges for Fortress Biotech (FBIO) over the last 4 years, with Sep 2023 value amounting to $177,000.

  • Fortress Biotech's Amortization of Deferred Charges fell 11.94% to $177,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $504,000, marking a year-over-year decrease of 35.71%. This contributed to the annual value of $353,000 for FY2023, which is 54.16% down from last year.
  • As of Q3 2023, Fortress Biotech's Amortization of Deferred Charges stood at $177,000, which was up 108.24% from $85,000 recorded in Q2 2023.
  • Over the past 5 years, Fortress Biotech's Amortization of Deferred Charges peaked at $221,000 during Q1 2021, and registered a low of $85,000 during Q2 2023.
  • For the 3-year period, Fortress Biotech's Amortization of Deferred Charges averaged around $173,091, with its median value being $177,000 (2023).
  • As far as peak fluctuations go, Fortress Biotech's Amortization of Deferred Charges surged by 47.33% in 2021, and later tumbled by 60.47% in 2023.
  • Over the past 4 years, Fortress Biotech's Amortization of Deferred Charges (Quarterly) stood at $205,000 in 2020, then decreased by 19.51% to $165,000 in 2021, then decreased by 8.48% to $151,000 in 2022, then decreased by 11.94% to $177,000 in 2023.
  • Its Amortization of Deferred Charges was $177,000 in Q3 2023, compared to $85,000 in Q2 2023 and $91,000 in Q1 2023.